Open Trials at Pacific Cancer Care

Pacific Cancer Care is driven by a vision to be the leader for the treatment of cancer in the Monterey County. Our clinicians and investigators identify and conduct Phase I-IV treatment options that are new and innovative, and that will positively impact our patients. Below is a list of clinical trials currently available at Pacific Cancer Care.
For more information regarding clinical trial opportunities, please contact Monica Castillo, Clinical Research Manager, at mocastillo@pacificcancercare.com or call her at (831) 375-4105 ext. 1077

Breast Cancer
NCT #03155997
MonarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Gastric or Gastroesophageal Junction (GEJ)
NCT #03653507
Glow: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

High-Risk Multiple Myeloma
NCT #03104270
CA204-187: A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone among high risk Relapsed/Refractory Multiple Myeloma Patients

Multiple Myeloma
NCT #03110822
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients

Non-Small Cell Lung Cancer
NCT #03302234
KEYNOTE-598: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS ≥ 50%)

NCT #03425643
KEYNOTE-671: A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer

KEYNOTE-789: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants

Blood Cancer Research Partnership with Dana-Farber Cancer Institute

High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
NCT #03236428
Pilot Study of the CD38 Antibody Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma